HSBC Holdings
CHRS icon

HSBC Holdings’s Coherus Oncology CHRS Stock Holding History

HSBC Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$158K Sell
91,895
-2,474
-3% -$4.39K ﹤0.01% 2667
2025
Q4 		$135K Buy
94,369
+2,370
+3% +$3.45K ﹤0.01% 2750
2025
Q3 		$149K Sell
91,999
-10,297
-10% -$11.5K ﹤0.01% 2549
2025
Q2 		$74.9K Sell
102,296
-2,691
-3% -$2.32K ﹤0.01% 2889
2025
Q1 		$85K Buy
104,987
+46
+0% +$53 ﹤0.01% 2842
2024
Q4 		$149K Buy
104,941
+3,785
+4% +$4.25K ﹤0.01% 2797
2024
Q3 		$106K Sell
101,156
-2,027
-2% -$2.78K ﹤0.01% 2787
2024
Q2 		$179K Buy
103,183
+9,905
+11% +$19.9K ﹤0.01% 2597
2024
Q1 		$223K Sell
93,278
-6,586
-7% -$16.2K ﹤0.01% 2621
2023
Q4 		$320K Buy
99,864
+16,535
+20% +$44.3K ﹤0.01% 2249
2023
Q3 		$313K Buy
83,329
+39,669
+91% +$183K ﹤0.01% 2201
2023
Q2 		$188K Sell
43,660
-2,904
-6% -$17.1K ﹤0.01% 2336
2023
Q1 		$315K Buy
46,564
+1,469
+3% +$11.4K ﹤0.01% 2215
2022
Q4 		$340K Buy
45,095
+31,339
+228% +$241K ﹤0.01% 2476
2022
Q3 		$137K Sell
13,756
-35,602
-72% -$360K ﹤0.01% 2709
2022
Q2 		$363K Buy
49,358
+15,205
+45% +$132K ﹤0.01% 2528
2022
Q1 		$449K Buy
+34,153
New +$434K ﹤0.01% 2499
2021
Q3 		– Sell
-10,556
Closed -$147K – 3006
2021
Q2 		$147K Buy
+10,556
New +$149K ﹤0.01% 2805
2021
Q1 		– Sell
-15,446
Closed -$269K – 2777
2020
Q4 		$269K Buy
+15,446
New +$275K ﹤0.01% 2640
2020
Q3 		– Sell
-12,871
Closed -$230K – 2734
2020
Q2 		$230K Sell
12,871
-3,286
-20% -$55.6K ﹤0.01% 2272
2020
Q1 		$259K Buy
16,157
+6,044
+60% +$112K ﹤0.01% 2139
2019
Q4 		$182K Sell
10,113
-6,552
-39% -$121K ﹤0.01% 2835
2019
Q3 		$338K Buy
+16,665
New +$333K ﹤0.01% 2555

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

HSBC Holdings's CHRS Position: Q1 2026 in Review

HSBC Holdings reduced its Coherus Oncology (CHRS) stake by 2.6% in Q1 2026, selling an estimated $4.39K and leaving 91,895 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #2667.

HSBC Holdings first reported a position in CHRS in Q3 2019 and has held it in 23 quarters since. The position peaked at $449K in Q1 2022. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • HSBC Holdings held 91,895 shares of Coherus Oncology worth $158K as of Q1 2026.
  • HSBC Holdings sold 2,474 Coherus Oncology shares in Q1 2026, an estimated $4.39K.
  • Coherus Oncology made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2667 holding.
  • HSBC Holdings first reported a position in Coherus Oncology in Q3 2019 and has held it in 23 quarters since.
  • HSBC Holdings's Coherus Oncology position peaked at $449K in Q1 2022.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.